Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 69.24M P/E - EPS this Y - Ern Qtrly Grth -
Income -29.34M Forward P/E -3.57 EPS next Y 6.30% 50D Avg Chg 29.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 67.00%
Dividend N/A Price/Book 1.50 EPS next 5Y - 52W High Chg -24.00%
Recommedations 2.00 Quick Ratio 2.25 Shares Outstanding 69.88M 52W Low Chg 138.00%
Insider Own 4.57% ROA -54.15% Shares Float 66.31M Beta 0.70
Inst Own 11.41% ROE -108.44% Shares Shorted/Prior 718.39K/752.51K Price 1.07
Gross Margin - Profit Margin - Avg. Volume 153,230 Target Price 8.97
Oper. Margin - Earnings Date Nov 12 Volume 236,640 Change -0.93%
About Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Cardiol Therapeutics Inc. News
11/18/24 Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
11/13/24 Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index
10/22/24 Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis
10/11/24 Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option
10/10/24 Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares
10/09/24 Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares
10/08/24 Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
09/24/24 Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis
09/10/24 Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024
07/12/24 We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate
06/27/24 Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders
06/25/24 Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT
06/17/24 Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
06/13/24 Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
05/14/24 Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
04/02/24 Cardiol Therapeutics Announces Year-End 2023 Update on Operations
02/21/24 Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
02/15/24 Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
01/24/24 Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market
01/09/24 Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
CRDL Chatroom

User Image Lorenzo1234567 Posted - 9 minutes from now

$CRDL

User Image Lorenzo1234567 Posted - 2 minutes from now

$CRDL You can guarantee FDA approval here. As i stated before RFK takes over/rebrands the FDA soon. He has always been skeptical of many vaccines and there potential side effects, specifically the Covid vaccine. Turns out he was right..Hmm A new landmark drug thats treats this, derived from CBD. RFK has preached CBD/Marijuana for medicinal value. Perfect storm. Can you say fast track approval?? Can you say revenge??

User Image Theo77 Posted - 3 minutes ago

$CRDL

User Image Theo77 Posted - 29 minutes ago

$CRDL

User Image Theo77 Posted - 1 hour ago

$CRDL

User Image ElieoG Posted - 2 hours ago

$CRDL so 2 more years of waiing or a little less hophelly .If badluck strikes and they are not approved can they contest the decision and ask for a second verdict?

User Image StreetwiseReports Posted - 6 hours ago

Analyst Says Biotech's Data Supports Advancement Into Phase III: https://ow.ly/LtU550UavAw Cardiol Therapeutics recently released updated Phase II data from the MAvERIC trial testing CardiolRx in recurrent pericarditis, according to a Leede Financial Inc. research note. $CRDL #biotechstocks

User Image Covode13 Posted - 6 hours ago

$CRDL if we end up gettting approval on one drug at least. What’s the estimated price will we end up at. Like $DRUG they jumped to 55 share price before falling back down to 30’s right now I believe it’s at.

User Image Covode13 Posted - 6 hours ago

$CRDL if we do go back below 1. I’ll be buying thousands of shares to lower my share price. So the next small move I’ll sell and rebuy. Only way to make profit on this long long intern hold for this to be approved

User Image Covode13 Posted - 6 hours ago

$CRDL

User Image TradeEd24 Posted - 8 hours ago

$CRDL What exactly is it going to take to move this ticker? Good news after good news and it is still red.

User Image Skichic Posted - 8 hours ago

$CRDL The market for the drug is huge!

User Image Skichic Posted - 8 hours ago

$CRDL Just bought a nice starter here. I have suffered from Pericarditis and sure the heck wish I’d had access to a drug like this. It’s an incredibly painful condition and all they have to treat it with is high dose NSAIDS every 4 hours, which eat your stomach up. Mine lasted 9 months and it can recur. It feels like you’re having a never ending heart attack.

User Image Blberry23 Posted - 9 hours ago

$CRDL COME RIP $TRIB BOTTOMED OUT BIOTECH

User Image Covode13 Posted - 9 hours ago

$CRDL

User Image StockQuen Posted - 9 hours ago

NASDAQ: $CRDL Add now, Big opportunity 12-Month Price Target: $10 based on a sum-of-the-parts valuation. This approach aligns with industry standards, utilizing a 3x sales multiple and a 9% WACC.

User Image HotStockNews Posted - 9 hours ago

NASDAQ: $CRDL add More in this DIP, News Coming INSIDER BUYING : Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each, indicating strong personal conviction in the company's potential.

User Image SeanWav Posted - 10 hours ago

$NVDA $CRDL The data reported today show that patients enrolled in MAvERIC-Pilot, despite the severity of their disease, experienced clinically relevant and rapid reductions in both their pericarditis pain and C-reactive protein levels that were maintained throughout the study. In addition, results demonstrated a substantial reduction in pericarditis episodes per year as compared to the patients' historical event rate prior to the study. Importantly, treatment was shown to be safe and well tolerated in a population who presented with significant disease burden

User Image SeanWav Posted - 10 hours ago

$CRDL “Importantly, treatment was shown to be safe and well tolerated in a population who presented with significant disease burden” More than BULLISH. to $20+++++ soon

User Image SeanWav Posted - 10 hours ago

$CRDL The data reported today show that patients enrolled in MAvERIC-Pilot, despite the severity of their disease, experienced clinically relevant and rapid reductions in both their pericarditis pain and C-reactive protein levels. Importantly, treatment was shown to be safe and well tolerated in a population who presented with significant disease burden.

User Image SeanWav Posted - 10 hours ago

$CRDL The data reported today show that patients enrolled in MAvERIC-Pilot, despite the severity of their disease, experienced clinically relevant and rapid reductions in both their pericarditis pain and C-reactive protein levels that were maintained throughout the study. In addition, results demonstrated a substantial reduction in pericarditis episodes per year as compared to the patients' historical event rate prior to the study. Importantly, treatment was shown to be safe and well tolerated in a population who presented with significant disease burden.

User Image SeanWav Posted - 10 hours ago

$CRDL great results submitted to American Heart Association. This is the final opportunity to grab some cheap shares . This should be $20++++ soon

User Image SeanWav Posted - 10 hours ago

$CRDL to $20+++ coming 🚀🚀🚀🚀💰💰💰💰

User Image SeanWav Posted - 10 hours ago

$CRDL 🚀🚀🚀💰💰💰💰💰

User Image Covode13 Posted - 11 hours ago

$CRDL

User Image Theo77 Posted - 11 hours ago

$CRDL

User Image StockQuen Posted - 11 hours ago

NASDAQ: $CRDL Breaking News: Cardiol Therapeutics’ Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

User Image Theo77 Posted - 11 hours ago

$CRDL

User Image BabyfaceMcD Posted - 12 hours ago

$CRDL nice moves $AZI hitting scanners easy over 3 today

User Image PDM21 Posted - 12 hours ago

$CRDL at what point to companies start make offers before the competition does? At what point does kiniska start to get concerned enough to be that company

Analyst Ratings
Roth MKM Buy Jun 26, 24
HC Wainwright & Co. Buy Jun 14, 24
HC Wainwright & Co. Buy Jun 7, 24
Canaccord Genuity Buy May 23, 24
HC Wainwright & Co. Buy May 14, 24
HC Wainwright & Co. Buy Apr 22, 24